Oxford Biomedica (LON:OXB) Receives Outperform Rating from Royal Bank Of Canada

Oxford Biomedica (LON:OXB)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank Of Canada in a report released on Wednesday,Digital Look reports. They presently have a GBX 1,170 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 103.48% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 price target on shares of Oxford Biomedica in a report on Tuesday. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 950 price target on shares of Oxford Biomedica in a report on Wednesday, March 11th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of GBX 604.32.

Oxford Biomedica Price Performance

Shares of LON OXB opened at GBX 575 on Wednesday. Oxford Biomedica has a twelve month low of GBX 305.50 and a twelve month high of GBX 952. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 116.74. The company has a market capitalization of £695.28 million, a price-to-earnings ratio of -21.36 and a beta of 1.10. The business has a 50 day simple moving average of GBX 604.82 and a 200-day simple moving average of GBX 664.32.

Oxford Biomedica (LON:OXB) last issued its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. As a group, equities research analysts expect that Oxford Biomedica will post -31.0799998 earnings per share for the current year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.